JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Impact of Bebtelovimab Treatment Timing on COVID-19 Outcomes in Ambulatory Solid Organ Transplant Recipients

  • 0Division of Infectious Diseases, Johns Hopkins University, Baltimore, USA.
Transplant Infectious Disease : an Official Journal of the Transplantation Society +

|

November 16, 2024

|

November 16, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

Early bebtelovimab treatment for COVID-19 in solid organ transplant recipients (SOTRs) significantly lowered hospitalization risk. Late administration showed no benefit over no treatment, highlighting the importance of timely COVID-19 therapies for SOTRs.

Area Of Science

  • Immunology
  • Infectious Diseases
  • Transplantation Medicine

Background

  • Bebtelovimab treatment for COVID-19 in solid organ transplant recipients (SOTRs) showed varied outcomes during Omicron BA.2-BA.5 waves.
  • The impact of bebtelovimab administration timing on SOTR outcomes remains unclear.

Purpose Of The Study

  • To compare COVID-19 hospitalization outcomes in SOTRs receiving early bebtelovimab (≤2 days from diagnosis), late bebtelovimab (3-7 days), or no bebtelovimab.
  • To assess the association between early bebtelovimab administration and 30-day COVID-19-related hospitalizations.

Main Methods

  • Retrospective cohort study of SOTRs with mild-to-moderate COVID-19.
  • Multivariable logistic regression and propensity score analysis were used to evaluate treatment effects.
  • The primary endpoint was 30-day COVID-19-related hospitalization.

Main Results

  • Early bebtelovimab treatment (n=162) was associated with significantly lower hospitalization risk compared to no bebtelovimab (n=71) (OR, 0.112; p=0.018).
  • Late bebtelovimab treatment (n=46) did not show a significant difference in hospitalization risk compared to no treatment.
  • The findings suggest that delayed bebtelovimab administration may not offer additional benefits over no treatment.

Conclusions

  • Early bebtelovimab administration in outpatient SOTRs reduced hospitalization risk compared to no treatment.
  • Late administration of bebtelovimab did not provide a significant advantage over no treatment.
  • The timing of COVID-19 therapies is critical for optimizing outcomes in SOTRs, even for treatments no longer authorized.

Keywords: